Thromb Haemost 2017; 117(10): 1836-1839
Schattauer GmbH
Risk stratification with the DAPT score: Carefully read the instructions and use as intended
Davide Capodanno
1
Division of Cardiology, Cardio-Thoracic-Vascular Department, Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
› Author Affiliations
References
1
Montalescot G,
Brieger D,
Dalby AJ.
et al. Duration of dual antiplatelet therapy after coronary stenting: A review of the evidence. J Am Coll Cardiol 2015; 66: 832-847.
2
Vries MJA,
van der Meijden PEJ,
Henskens YMC.
et al. Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2015; 115: 7-24.
3
Levine GN,
Bates ER,
Bittl JA.
et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Thorac Cardiovasc Surg 2016; 152: 1243-1275.
4 The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2014; 35: 2541-2619.
5
Capodanno D,
Angiolillo DJ.
Tailoring duration of DAPT with risk scores. Lancet 2017; 389: 987-989.
6
Yeh RW,
Secemsky EA,
Kereiakes DJ.
et al. Development and validation of a prediction rule for benefit and harm of Dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. J Am Med Assoc 2016; 315: 1735-1749.
7
Mauri L,
Kereiakes DJ,
Yeh RW.
et al. [DAPT] Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med 2014; 371: 2155-2166.
8
Kittelson JM,
Steg PG,
Halperin JL.
et al. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost 2016; 116: 544-553.
9
Lip GYH,
Lane DA.
Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 2016; 14: 1711-1714.
10
Chai-Adisaksopha C,
Hillis C,
Monreal M.
et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding A meta-analysis. Thromb Haemost 2015; 114: 819-825.
11
Roldan V,
Marín F.
Assessment of bleeding risk in acute ill medical patients An essential part of venous thromboembolism prevention. Thromb Haemost 2016; 116: 403-404.
12
Harada Y,
Michel J,
Lohaus R.
et al. Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. Thromb Haemost 2017; 117: 1989-1999.
13
Steg PG,
Mehta SR,
Jukema JW.
et al. RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011; 32: 2541-2554.
14
Piccolo R,
Gargiulo G,
Franzone A.
et al. Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. Ann Intern Med 2017; 348: g3859.
15
Kietzmann T.
Myocardial infarction in elderly patients: How to assess their bleeding risk?. Thromb Haemost 2015; 114: 869-871.
16
Didier R,
Morice MC,
Barragan P.
et al. 6– Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin. JACC Cardiovasc Interv 2017; 10: 1202-1210.
17
Nakamura M,
Iijima R,
Ako J.
et al. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. JACC Cardiovasc Interv 2017; 10: 1189-1198.
